耳穴疗法与甲芬那酸治疗原发性痛经的随机临床试验比较
该随机临床试验将83名原发性痛经学生分为耳穴疗法组与甲芬那酸组,比较两种干预对疼痛严重程度及全身症状的影响。结果显示耳穴疗法组在干预第一和第二周期VAS平均疼痛强度显著低于甲芬那酸组,第二周期VMS分级差异显著;耳穴疗法组无受试者处于痛经3级,而甲芬那酸组仍有16.7%。
要点
- 耳穴疗法组VAS平均疼痛强度在第一和第二干预周期均显著低于甲芬那酸组。
- 第二周期耳穴疗法组无痛经3级(常见全身症状)受试者,甲芬那酸组为16.7%。
- 两组全身症状频率无显著差异,但耳穴疗法组恶心、头痛和愤怒频率显著降低。
核心结论
- 耳穴疗法组的VAS平均疼痛强度低于甲芬那酸组,且65.9%的耳穴疗法组受试者处于痛经0级和1级,因并发症较少且对原发性痛经更有效而推荐耳穴疗法。
研究设计与样本
- 随机临床试验,83名学生随机分为两组;耳穴疗法组每周一次耳电刺激,持续两个月经周期,经期临近时在压力点埋耳豆并于疼痛时按压;甲芬那酸组在月经初始症状出现时服用甲芬那酸胶囊直至疼痛减轻。
主要发现
- 耳穴疗法组VAS平均疼痛强度在干预第一和第二周期均显著低于甲芬那酸组。
- 两组VMS分级在第二干预周期存在显著差异。
- 第二干预周期耳穴疗法组无受试者处于痛经3级,甲芬那酸组16.7%受试者仍处于痛经3级。
- 两组原发性痛经全身症状频率无显著差异。
- 两组疲劳和腹泻频率均显著下降,耳穴疗法组恶心、头痛和愤怒频率显著降低。
关键数值与推荐
- 疼痛强度采用视觉模拟量表(VAS)和语言多维评分系统(VMS)测量,全身症状采用VMS及是/否问卷评估。
- 第二干预周期耳穴疗法组痛经3级比例为0%,甲芬那酸组为16.7%。
- 65.9%的耳穴疗法组受试者处于痛经0级和1级。
临床怎么用
- 对于原发性痛经患者,耳穴疗法可作为减少并发症且对疼痛强度有效的非药物止痛选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary dysmenorrhea (PD) is the most common complaint in young women and adolescents. Side effects of non-steroidal anti-inflammatory drugs can limit their use. Therefore, non-pharmacological pain relief methods such as auriculotherapy may play an important role in PD management. This study was conducted to compare the effect of auriculotherapy and mefenamic acid on the severity and systemic symptoms of PD. METHODS: In a randomized clinical trial, 83 students were randomized into two groups. In the auriculotherapy group, electrical stimulation of the ear was conducted once a week for two menstrual cycles. In each cycle close to menstruation, ear seeds were inserted on pressure points to be pressed in times of pain. In the mefenamic acid group, subjects took mefenamic acid capsules upon seeing the initial symptoms of menstruation until the pain reduces. The primary outcomes were mean pain intensity and systemic symptoms associated with it. Pain intensity was measured through the visual analog scale (VAS) and the verbal multidimensional scoring system (VMS). Systemic symptoms were assessed using VMS, as well as the yes/no question form. RESULTS: Mean pain intensity with the VAS was significantly lower in the auriculotherapy group than the mefenamic acid group in the first and second cycles of intervention. There was a significant difference in VMS grade between both groups during the second cycle of intervention. In terms of the systemic symptoms in the second cycle of intervention, no subjects had dysmenorrhea grade 3 (common systemic symptoms) in the auriculotherapy group. Whereas in the mefenamic acid group, 16.7% of the subjects still had dysmenorrhea grade 3. There was no significant difference between the two groups in the frequency of systemic symptoms of PD. There was a significant decrease in the frequency of fatigue and diarrhea in both groups. However, there was a significant reduction in the frequency of nausea, headache, and anger in the auriculotherapy group. CONCLUSION: Mean pain intensity with the VAS was lower with the auriculotherapy. Also, 65.9% of auriculotherapy group subjects were in the dysmenorrhea grades 0 and 1. Therefore, auriculotherapy is recommended because of its fewer complications and more effect on PD. TRIAL REGISTRATION: ClinicalTrials.gov IRCT20181207041873N1. Registered on February 24, 2019. https://en.irct.ir/user/trial/35967/view.
引用
- Vahedi M, Hasanpoor-Azghady SB, Amiri-Farahani L, et al. Comparison of effect of auriculotherapy and mefenamic acid on the severity and systemic symptoms of primary dysmenorrhea: a randomized clinical trial. Trials. 2021. PMID: 34565433. doi:10.1186/s13063-021-05622-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。